Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Tofacitinib preferentially inhibits receptor signaling through JAK3 and JAK1, relative to JAK2. In the 2-year rat carcinogenicity study, there were tofacitinib, dose-related increases in the incidences of testicular Leydig cell hyperplasia and benign adenomas in male rats, and decreased incidences of mammary tumors and duct dilatation/galactocele in female rats. Such findings in rats are typical of agents, such as dopamine agonists, which decrease prolactin (PRL) activity. Since prolactin signals through the JAK2 pathway, we hypothesized that these findings were off-target effects due to inhibition of PRL signaling via JAK2. The studies reported here were designed to investigate the interruption of PRL signaling pathways in Leydig cells. In isolated primary rat Leydig cells, PRL increased phosphorylated Signal Transducer and Activator of Transcription-5 protein, and mRNA levels for luteinizing hormone receptor. Tofacitinib, at concentrations observed in the rat carcinogenicity study, dose-dependently inhibited these effects. These observations illustrate a novel mechanism, the inhibition of prolactin signaling by which modulation of JAK activity can modulate PRL signaling pathways to induce Leydig cell tumors in rats. Since human Leydig cells lack this PRL dependence for normal function, these rodent tumors do not indicate a health risk to human patients.
The Janus kinase (JAK) family, including JAK1, JAK2, JAK3, and tyrosine kinase 2 (TyK2), is a group of cytoplasmic tyrosine kinases that mediate signal transduction of various ligands including cytokines, hormones, and growth factors. Binding of the ligand to its receptor leads to autophosphorylation of the associated JAKs and the receptor which then serve as docking sites for the Signal Transducer and Activator of Transcription (STAT) family of transcription factors. The STATs are then phosphorylated and translocate to the nucleus where they bind to specific gene promoters to activate transcription of a range of target genes (Rawlings et al., 2004; Watson and Burdon, 1996) . Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis. In cellular settings, where JAKs signal in pairs or multimers, tofacitinib preferentially inhibits signaling by JAK complexes associated with JAK3 and/or JAK1 with relative functional selectivity over receptors that signal via pairs of JAK2 (Meyer et al., 2010) .
In a 2-year rat carcinogenicity study, tofacitinib administration was associated with dose-related increases in the incidences of testicular Leydig cell hyperplasia and adenomas in V C The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com male rats. The data reported here are from the rat carcinogenicity study and from follow-on investigational experiments aimed at testing the hypothesis that tofacitinib modulation of prolactin signaling (PRL) via JAK2 is the likely cause of Leydig cell tumors (LCTs) observed in the rat carcinogenicity study. Female rats in the carcinogenicity study had decreased incidences of mammary tumors (both fibroadenomas and carcinomas) and duct dilatation/ galactocele (dilated and cystic mammary ducts filled with proteinaceous secretory fluid; also referred to as "dilated ducts" or "cystic change"). This pattern of increased LCTs in males, and decreased mammary tumors and galactocele in females in rats is characteristic of agents, such as dopamine agonists, that cause hypoprolactinemia (Steele, 1997) .
Prolactin signals to cells via a membrane-bound receptor coupled to JAK2 (Chilton and Hewetson, 2005) . Since the LCTs were seen at circulating tofacitinib concentrations high enough to significantly inhibit JAK2, our attention focused on PRL signaling via JAK2. PRL binding to its receptor stimulates JAK2 to phosphorylate STAT5. Phosphorylated STAT5 then translocates to the nucleus and impacts gene transcription. Thus, if JAK2 activity is blocked by elevated concentrations of tofacitinib in rats, the PRL signaling to the cell would be reduced or blocked.
Normal PRL signaling helps maintain the levels of luteinizing hormone (LH) receptor on rat Leydig cells. When plasma PRL levels were reduced, LH receptor levels on rat Leydig cells were also reduced (Aragona et al., 1977; Grizard et al., 1983; Waeber et al., 1983) . We might expect that blocking JAK2 activity would have functionally similar consequences.
Over a prolonged time period, reduced LH receptor density would lower testosterone (T) output from the Leydig cells, and the central nervous system and pituitary axis would increase LH secretion to compensate and to maintain circulating T levels (rev. in Clegg et al., 1997; Cook et al., 1999) . Chronically elevated LH levels in rats appears to drive rat Leydig cell divisions and hyperplasia (eg, Christensen and Peacock, 1980; Walsh, 1997; rev. in Cook et al., 1999) .
Thus, our hypothesis for the generation of the LCTs was that the high systemic concentrations of tofacitinib in the 2-year carcinogenicity study blocked JAK2/STAT5 activity, thereby blocking the tonic prolactin-mediated maintenance of LH receptor number, thus reducing T output, which in turn drove a chronic increase in LH which eventually produced these rat LCTs. Since confidently detecting a modest but biologically-important increase in circulating LH would require potentially hundreds of animals (Chapin and Creasy, 2012) , we focused our efforts on determining whether some expected key components of the PRL signaling cascade in Leydig cells would be affected in a manner consistent with the above hypothesis. The focus of the study was effects on the PRL-dependent phosphorylation of STAT5 and the downstream expression of the LH receptor, both of which should be reduced in rat Leydig cells exposed to tofacitinib if the hypothesized mechanism was active.
The results showed a clear PRL-stimulated increase in the amount of phosphorylated STAT5 and expression of LHR mRNA in isolated primary rat Leydig cells, both of which were progressively inhibited by increasing concentrations of tofacitinib, including those observed in rats in the carcinogenicity study. In addition, literature review revealed the mechanism of hypoprolactinemia and decreased Leydig cell LH receptor is operative in dopamine agonists.
MATERIALS AND METHODS
All animal care and experimental procedures of this study were conducted in compliance with the U.S. Animal Welfare Act and performed in accord with the standards of the Institute of Laboratory Animal Resources Guide (1996) and were approved by an Institutional Animal Care and Use Committee. The facilities in which these studies were conducted are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
Rat 2-Year Carcinogenicity Study A Good Laboratory Practice compliant rat carcinogenicity study was conducted at Covance Laboratories Inc. (Madison, Wisocnsin) between 2008 and 2010. Male and female Crl:CD(SD) rats from Charles River Laboratories (Portage, Michigan) were 46-53-days old at initiation of treatment, and their body weights ranged from 178 to 299 g for males and 148-230 g for females.
Rats were housed individually in solid-bottom polycarbonate cages with paper bedding and offered water and Certified Rodent Diet no. 8728C (Harlan Laboratories, Inc.) ad libitum. Environmental controls were set to maintain animal room temperature of 18-26 C, a relative humidity of 30-70%, at least 10 room air changes/hour, and a 12-h light-dark cycle. The citrate salt of tofacitinib was formulated as a suspension in a vehicle of 0.5% (w/v) methylcellulose, in reverse osmosis water. Dose formulations were confirmed to be stable for at least 15 days under room temperature and refrigerated conditions. Homogeneity of analyzed samples varied from 97.5 to 104% of the theoretical value, and mean concentrations varied from 97.0 to 105% of intended value.
Doses were based on results from a previous 6-month rat study; the high dose was anticipated to be a maximally tolerated dose. Animals were dosed once daily by oral gavage at a volume of 10 ml/kg at doses of 0 (vehicle control), 10, 30, and 75/ 100 mg/kg/d. High-dose males were administered 75 mg/kg/d throughout the study. Due to infection-related deaths, the high dose in females was reduced in Week 19 from 100 to 75 mg/kg/d for the remainder of the study. There were 70 animals/sex/ group in the vehicle-control and high-dose groups, and 60/sex/ group in the low-and intermediate-dose groups. Dose administration was based on the most recent body weight. Body weight was recorded weekly from Weeks 1 to 26, and once every 4 weeks thereafter. Based on mortality, the high-dose males were euthanized in Week 94, the remaining males in Week 98 and the females in Week 103. To assess systemic exposure to tofacitinib during Week 26, blood samples were obtained via a jugular vein from the first 3 animals/sex/time point in the vehicle control groups at approximately 0.5, 2, and 8 h postdose, and from the first 3 animals/sex/time point in the tofacitinib-treated groups at approximately 0.5, 1, 2, 4, 8, and 24 h postdose. Serum samples were analyzed for tofacitinib concentration using a validated liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) method, and toxicokinetic parameters were calculated using WinNonlin 4.0.1 software (Pharsight Corporation, Mountain View, California). The area under the serum concentration-time curve (AUC 24 ) was estimated using the linear trapezoidal approximation. There were no quantifiable concentrations of tofacitinib in samples analyzed from control dose group animals.
A necropsy was performed on all animals that died or were euthanized at an unscheduled interval. Euthanized animals were anesthetized with sodium pentobarbital, weighed, and exsanguinated. At scheduled termination all surviving animals were anesthetized with sodium pentobarbital, weighed, and exsanguinated. A standard broad panel of 54 protocol-specified tissues (when present) from all animals were collected, embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically by board certified veterinary pathologists including a primary study pathologist and a peer review pathologist.
Animals and Chemicals-Leydig Cells Investigative Studies
Adult male Sprague Dawley rats [Crl:CD (SD)] were obtained from Charles River Breeding Laboratories, Kingston, New York at 86-156 days of age. Upon arrival, rats were acclimated for at least 1 week before use and were housed individually in polycarbonate cages. Certified Rodent Diet 5002 (Purina Mills, Inc., Gray Summit, Missouri, USA) and filtered Groton city tap water were available ad libitum, and the room was on a 12-h light-dark cycle.
All chemicals were purchased from Sigma-Aldrich (St Louis, Missouri) unless noted otherwise, and all were of the highest purity available. Ovine PRL (NDDK-oPRL-21) was the generous gift of Dr Alan F. Parlow, National Hormone and Pituitary Program, Torrance, California. The oPRL was formulated in 30 mM NaHCO 3 in 0.15 M NaCl, and stored frozen at À20 C for no more than 2 weeks before use. Tofacitinib was dissolved in DMSO and cell culture medium to working concentrations of 0.1-3.33 mM. These were stored at À20 C when not in use, and were diluted 1:100 with cell culture medium for cell dosing. The final concentration of DMSO in the cell exposures was 0.1%. At the end of dosing the stocks were moved to À70 C and stored for $3 months prior to analysis by LC-MS/MS. That analysis found that the dilutions were between 64 and 76% of their intended concentrations. The concentrations presented in this report represent the adjusted concentrations.
Leydig Cell Preparations
Preparation of rat testicular Leydig cells were performed using methods as previously described in Biegel et al., (1993) and Salva et al. (2001) . Adult male Sprague Dawley rats (n ¼ 2 per isolation) were euthanized by CO 2 asphyxiation and their testes removed. Each testis was perfused via the testicular artery with 1.0 mg/ml collagenase (CLS2, Worthington Biochemical, Lakewood, New Jersey) in M-199 media, containing 0.1% bovine serum albumin (BSA), 25 mg/ml soybean trypsin inhibitor and 0.1% v/v antioxidant supplement. Following perfusion, testes were placed into 50 ml conical centrifuge tubes (2 testes per tube) with 5 ml of M-199 media and 0.1% v/v antioxidant supplement, then shaken at 90 cycles per minute for 10 min in a 34 C water bath. The mass of seminiferous tubules were further dispersed by adding 5 ml of M-199 media, containing 0.5 mg/ml collagenase, 0.1% BSA, 25 mg/ml soybean trypsin inhibitor and 0.1% v/v antioxidant supplement to each tube and shaking for 15 additional minutes (final collagenase concentration, 0.25 mg/ml). Following the collagenase digestion, Hanks Balanced Salt Solution (HBSS, Invitrogen, www.lifetechnologies.com) containing 1.0% w/v BSA was added to each tube to bring the final volume up to 50 ml. The tubes were inverted 5 times and after 1 min of unit gravity sedimentation, the seminiferous tubules settled to the bottom of the tube and the supernatant with the liberated Leydig cells was collected by aspiration with a pipette. This washing procedure was repeated 2 more times to ensure that all available Leydig cells were obtained (Salva et al., 2001) . The resulting supernatants were centrifuged at 250Âg at 4 C for 10 min. The cell-free supernatants were carefully decanted and discarded and the pelleted cells were re-suspended in 10 ml M-199 media, all pellets from 1 animal were pooled and added to the top of Percoll density gradients (2 testes per gradient). Each gradient was prepared 1-24 h before use in a 50 ml conical centrifuge tube and consisted of four 10 ml densities; 1.035, 1.076, 1.085, and 1.095 g/ml Percoll (GE Healthcare, www.gelifesciences.com) diluted with 10Â HBSS. Following the addition of cells, each gradient tube was centrifuged at 800Âg at 4 C for 30 min. Most of the viable Leydig cells migrated to the boundary between the 1.085 and 1.095 g/ml density layers, or approximately at the 13 ml mark of the 50 ml conical centrifuge tube. This portion of the gradient was collected by slowly aspirating and discarding the upper layers, then aspirating and retaining the layers between the 13 and 12 ml marks. These cells were transferred to a fresh 50-ml conical tube, then immediately diluted 2-to 3-fold with unmodified M-199 media and pelleted by centrifugation at 250Âg at 4 C for 10 min. The cell-free supernatants were decanted and discarded, and the pelleted Leydig cells were resuspended in 2 ml of RPMI-1640 media containing 10% fetal bovine serum (FBS). Cells from all tubes in one isolation were combined, then counted and tested for viability using Trypan Blue exclusion in a CEDEX Analyzer cell counter (Innovatis GmbH Co, Germany). Purity of the isolated Leydig cells was assessed in 25 ll pooled-cell suspensions, air-dried on a glass slide and stained for 3b-hydroxysteroid dehydrogenase activity as described by Biegel et al. (1993) .
Leydig Cell Culture Conditions
Cells were plated on 12-well collagen-coated plates (BD Biocoat, Cat No. 354500) in RPMI-1640 media, containing 10% FBS (Gibco, www.lifetechnologies.com), 1% v/v antibiotic/antimycotic solution and 0.1% v/v antioxidant supplement. Cells were plated 2-4 Â 10 5 cells per well in 12-well plates, in a reduced volume (0.4 mL) of FBS media to facilitate attachment. After 2 h, an additional 0.6-1.6 ml of FBS media was added to each well. Sixteen to twenty-four hours after initial plating, cells were washed once with PBS and fed with serum-free media containing RPMI-1640 media, 1% v/v antibiotic/antimycotic solution, 0.1% v/v antioxidant supplement. For all subsequent days in culture, cells were maintained using serum-free media supplemented as above. Cells were incubated at 5% CO 2 in room air at 90% relative humidity and 34 C.
In Vitro Leydig Cell Exposures
To assess the phosphorylation status of STAT5, cells were refed with 0, 60, and 100 ng/ml oPRL (3 wells per concentration) in serum-free supplemented medium for 20 min and then harvested. To test the ability of tofacitinib to inhibit the PRLinduced phosphorylation of STAT5, additional 0, 60, and 100 ng oPRL/ml wells (3 wells/condition) were exposed to 10.0, 2.2, 0.76, 0.21, and 0.074 lM concentrations of tofacitinib for 1 h prior to and during the 20-min prolactin treatment period. At the end of the incubation, the medium was aspirated and the cells were rinsed with ice cold PBS and lysed according to the instructions supplied with Milliplex MAP kit No. 480680 (EMD Millipore Co, Billerica, Massachusetts). Cell extracts were stored at -20 C until analysis. Three separate replicate studies were performed using separate Leydig cell isolations.
Analysis of STAT5 Phosphorylation STAT5 occurs in 2 forms, STAT5A and STAT5B, which have 96% sequence similarity in mice (Liu et al., 1995) . The assay used does not distinguish between phosphorylated STAT5A and STAT5B. STAT5B was shown to be involved in PRL signaling in a mouse Leydig cell line; it is not known which STAT5 may be involved in PRL signaling in rat Leydig cells (Kanzaki and Morris, 1998) . To analyze STAT5A/B phosphorylation, protein concentrations were obtained using a standard BCA assay (Thermo Scientific/Pierce BCA assay, Waltham, Massachusetts). Cell extracts were diluted 1:1 in Milliplex Map Assay Buffer 2 and the subsequent steps were as directed in the Millipore assay kit (Millipore Co Cat no. 43-041) using STAT5A/B antibody capture beads (Millipore Co Cat no. 64-641A). At the end of the procedure, the beads were resuspended in 150 ll/well of Milliplex Map Assay Buffer 2 and analyzed on a Bio-Rad Bioplex instrument. The settings used for the Bio-Rad Bioplex were with a sample size of 100 ml and a "time out" period of 60 s. The rest of the settings for the Bioplex were left at default and the bead region for the STAT5A/B beads was "35". All results were normalized to 2000 mg/ml based on initial protein concentration from the standard BCA assay.
Analysis of LH Receptor mRNA
At the end of the in vitro cell incubation period, cells were rinsed with calcium-free PBS and lysed in Qiagen Buffer RLT Plus with Beta-mercaptoethanol (Qiagen, Valencia, California) and stored at 4 C or colder until further use. Total RNA was prepared using the QiagenTotal RNeasy Plus Mini kit following the manufacturer's recommended protocol. All RNA was converted to cDNA using Applied Biosystem (AB) High Capacity cDNA Reverse Transcription Kit in a 100 ll reaction. In total 3 ll of this reaction was loaded into a 20 ll TaqMan QPCR reaction using the stand- replicates were run for each sample/treatment. The real time RT-PCR amplifications were run on an ABI Prism 7900HT Sequence Detection System (AB) with a TaqMan Low Density Array Upgrade and an Automation Accessory. Real-time RT-PCR data were quantified using the SDS 2.4 Enterprise software package (AB). Results from each plate were quantified concurrently, using an automatic baseline and threshold to determine the cycle thresholds (C t s). Visual inspection of automatic settings was conducted for each dataset and adjusted as necessary. Assays that did not yield a cycle threshold for less than 40 cycles were treated as negative results. For our analysis, we used the delta delta Ct relative quantification method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008) built into the AB Software. Confidence intervals of 95% were based on the technical and biological replicates and were used to plot the x and y error bars in Microsoft Excel. All data were reported as fold change over concurrent control for each experiment. Four replicate experiments were performed, using separate Leydig cell isolations.
Statistical Analysis
For the carcinogenicity data, group incidences of each observed neoplastic lesion or combination were analyzed using a onesided Peto trend test and pairwise tests (treated versus control groups only) for evidence of a positive relationship between neoplasm incidence and dose. Survival among groups was compared using the nonparametric time adjusted log-rank method.
As pre-specified in the experimental protocol, there was no formal statistical testing for decreased tumor incidence rates or for incidence rates of non-neoplastic lesions. For the Leydig cell response data, all the data from the 3 (STAT5) or 4 (LHR mRNA quantitation) replicate experiments were averaged for presentation here. To account for experimental variation, the LHR data are presented as multiples of the untreated control value. Each endpoint (STAT phosphorylation, LH Receptor mRNA) was analyzed statistically using a 2-way analysis of variance model with oPRL concentration, tofacitinib concentration, and their interaction, as factors in the model. Depending on the nature of the comparisons, 2-different follow-up testing methods were used. First, to compare concentrations of tofacitinib to control for a given concentration of oPRL, sequential trend testing was conducted (Tukey et al., 1985) . To compare levels of oPRL in the absence of tofacitinib, pairwise t-tests were used. Both endpoints were logtransformed in order to stabilize variance. All analyses were conducted in R (Version 3.1.0).
RESULTS

Rat Carcinogenicity Study
Although this was a conventional carcinogenicity study with a full tissue list examined at termination, only those endpoints related to prolactin signaling are reported here. Other aspects of the carcinogenicity studies are publicly available in regulatory agency reviews (European Medicines Agency, 2013; U.S. Food and Drug Administration, 2012). Systemic exposures, survival, and histopathologic findings in male testes and female mammary glands from the rat carcinogenicity study are shown in Table 1 . The time-course of serum tofacitinib levels after oral gavage is shown in Figure 1 . Systemic exposures (C max 4.4-26 mM, C av 0.4-7.7 mM) assessed in Week 26 of the rat carcinogenicity study increased with increasing dose. Serum tofacitinib concentrations were similar to or greater than the concentrations subsequently demonstrated to inhibit STAT phosphorylation induced by prolactin in isolated rat testicular Leydig cells cultured in vitro.
Based on mortality, the high-dose males were euthanized in Week 94, the remaining males in Week 98, and the females in Week 103. Survival rates of 30% in male and female control groups were typical of those in 2-year studies with SpragueDawley rats (Cho et al., 2008; Hubert et al., 2000) . Lower survival in high-dose male and female groups was statistically significant in the males (P < .05), and was attributed to infections secondary to immunosuppression by tofacitinib at the high dose. Sufficient numbers of animals survived to adequately evaluate carcinogenicity.
Histopathologic evaluation of the testes showed a tofacitinib dose-related increase in testicular Leydig cell hyperplasia and adenomas in males (Table 1) . There was a statistically significant tofacitinib-related increase (P ¼ .0001 for trend test) in testicular adenoma. The incidence at 75 mg/kg/d significantly exceeded that in the vehicle control group (P ¼ .001) and also exceeded the mean (2.2%) and upper range (6.2%) for the spontaneous background incidence of testicular adenoma in Sprague-Dawley control groups from 10 recent carcinogenicity studies from the same laboratory. The incidence of Leydig cell adenomas at the middle dose of 30 mg/kg/d did not differ significantly from controls (P ¼ .068). However, it was slightly above the maximum historical control rate (6.2%), and based on the incidence of interstitial cell hyperplasia (a biological continuum with interstitial cell tumor) in this study, a proliferative effect (hyperplasia and/or adenoma) on interstitial cells of the testis was also evident in males at 30 mg/kg/d. The incidence of LCTs at the low dose of 10 mg/kg/d did not differ significantly from the concurrent control group, was well within the historical spontaneous rate, and is considered a no-observed-effect level for Leydig cell proliferative effects in the carcinogenicity study. There were no additional tofacitinib-related testicular findings, or tofaticinib-related effects on other male reproductive organs, in the rat carcinogenicity study.
In the mammary glands of female rats from the carcinogenicity study, there were tofacitinib dose-related decreases in the spontaneous background incidences of galactocele (dilated and cystic mammary ducts filled with proteinaceous secretory fluid), fibroadenoma, and carcinoma. The statistical significance of these decreases was not tested because, by protocol design, statistical tests were only performed for neoplastic lesions, and only by 1-tailed test to detect an increased tumor incidence.
Leydig Cell In Vitro Response to PRL and Tofacitinib
For the experiments reported here, cell viability ranged from 70.1 to 79.2% with an average of 76.0%. Cell purity ranged between 82 and 90.4%, with an average of 85.3%. Figure 2 presents the responses for the phosphorylation of STAT5 after oPRL treatment, and its inhibition by tofacitinib. All 3 experimental replicates were averaged and presented. Concentrations of 60 and 100 ng/ml oPRL produced a concentration-related increase in the amount of phosphorylated STAT5 in these primary Leydig cells, and both these increases were blocked by tofacitinib in a concentrationdependent fashion. Figure 3 presents the response for LHR mRNA levels to oPRL treatment, and the attenuation of that response by tofacitinib. Concentrations of 10, 20, or 60 ng/ml of oPRL alone produced a C max , maximum observed serum concentration; C av , average serum concentration from 0 to 24 h; NOAEL, No observed adverse effect level.
Unbound serum concentrations (means at 26 weeks) in mM were calculated from total serum concentrations in ng/ml using an unbound fraction in rat serum of 0.85 and molecular weight of 312.4. Histopathology findings are expressed as incidence: (number of animals in which finding was observed)/(number of animals examined); number of animals examined includes all animals in the study, those that survived to scheduled termination and those that died prematurely. Statistical testing for the decreases in mammary findings in females was not conducted because the experimental protocol specified only 1-tailed tests for detection of increases in tumor incidence.
*P < .05 compared with control group by the nonparametric time adjusted log-rank method. concentration-dependent increase in the amount of LHR mRNA, and each increase was attenuated by increasing concentrations of tofacitinib. Addition of 0.07, 0.21, 0.76, 2.2, or 10 mM tofacitinib in the absence of prolactin had no statistically significant effect on the amount of LH receptor mRNA (data not shown).
DISCUSSION
The rat carcinogenicity study showed that the JAK inhibitor, tofacitinib, produced a clear dose-related increase in Leydig cell hyperplasia and adenomas in males, and dose-related decreases in mammary galactocele and mammary tumors in females. It was hypothesized that both of these might be causally explained through reduced PRL signaling via an offtarget inhibition of JAK2/STAT5 activity observed at the supra-therapeutic concentrations used in safety studies. Our data are consistent with this hypothesis, showing that the high dose used in the carcinogenicity study produced tofacitinib blood levels that exceeded the rat JAK2 IC 50 for more than 8 h/d, while the intermediate dose exceeded the rat JAK2 IC 50 for about 6 h/d. At the lowest-observed-effect level dose of 30 mg/kg/d for increased incidence of Leydig cell hyperplasia and adenomas in male rats, the total (bound plus free) tofacitinib average serum concentration (C av ) was 1.7 mM (525 ng/ml). This is approximately 25 times the C av of 68 nM (21 ng/ml) observed in human rheumatoid arthritis patients at a tofacitinib dose of 5 mg twice a day (Xeljanz Canadian Product Monograph, 2014) . The JAK2/STAT5 pathway is the primary signaling pathway for PRL in the rat mammary gland (Watson and Burdon, 1996) . Increases in JAK2 and STAT5 phosphorylation in response to PRL have been described for a murine Leydig cell line (Kanzaki and Morris, 1998) , and in ram testes (Jabbour and Lincoln, 1999) but was not previously demonstrable in isolated juvenile primary rat Leydig cells (Kanzaki and Morris, 1998) . Thus, to test our hypothesis, it was important to demonstrate whether PRL can, indeed, stimulate STAT5 phosphorylation in rat Leydig cells, and whether PRL signaling via JAK2 could be blocked by tofacitinib at the concentrations achieved in the rat carcinogenicity study.
In the rat mammary gland, PRL is trophic for mammary tumors, and compounds which increase PRL levels also increase the rate of mammary tumors, while exposures which decrease serum PRL levels decrease the rate of mammary tumors (rev. in Harleman et al., 2012; Welsch and Aylsworth, 1983) . Thus, a decrease in PRL signaling would be expected to reduce mammary tumor incidence.
In the rat testis, PRL helps maintain LH receptor number and responsiveness (Aragona et al., 1977; Waeber et al., 1983) . Reducing LH receptor number would be expected to reduce the trophic drive to maintain testosterone secretion, and that reduced testosterone should produce a compensatory increase in serum LH levels (rev. in Prentice and Meikle, 1995) . Although there are reports of increased serum LH levels in rats treated with compounds (mesulergine and norprolac) known to cause LCTs (Prentice et al., 1992; Roberts et al., 1993) , LH is known to be episodically released (Ellis and Desjardins, 1982; Sodersten et al., 1983) and powering a study to confidently detect an increase in LH was judged to require too many animals (Chapin and Creasy, 2012) . Of additional concern were those literature reports which found only intermittent changes in LH (Yamada et al., 1994; Roberts et al., 1989; Cook et al., 1994) or no change at dose levels which produced tumors (Yamada et al., 1994) . Thus our focus turned to those more proximate pieces of the biochemical chain of events which might be explored.
PRL binding to its cell surface receptor causes receptor dimerization and JAK2 activation, which then phosphorylates the JAK kinases themselves, the receptor, and STAT5. The phosphorylated STAT5 then moves to the nucleus to affect transcription (rev. in Chilton and Hewetson, 2005) . If tofacitinib were inhibiting JAK2 activity, then it should reduce the amount of phosphorylated STAT5, which in turn might reduce the amount of mRNA for one of the target genes, that of the LH receptor. Indeed, we found that increasing concentrations of tofacitinib progressively reduced the amount of phosphorylated STAT5 induced by PRL, and the amount of LHR mRNA induced by PRL. Both of these effects in isolated Leydig cells were observed at concentrations which overlap with those observed in the mid-and high-dose rats in the carcinogenicity study. It is also worth noting that the approximate IC 50 for the ability of tofacitinib to block the PRL stimulation (Figs. 2 and 3) appears to be near or below the IC 50 for the inhibition of STAT phosphorylation induced by GM-CSF in whole blood cells (Figure 1) , suggesting a greater sensitivity in isolated Leydig cells to the effects of tofacitinib compared with the targeted circulating immune cells. The issue of relevance of these rat LCTs to human health has been extensively addressed (see reviews by Clegg et al., 1997 and Cook et al., 1999) . Rats differ from humans in PRL and Leydig cell biology at several critical points along the path to tumor development: PRL or PRL signaling is required to maintain LH responsiveness in rats (Zipf et al., 1978) , but human Leydig cells have no detectable PRL binding to interstitial cells (Wahlstrom et al., 1983) . Several dopamine agonists used in the clinic (mesulergine, norprolac, and oxolinic acid,) which reduce PRL levels, have been shown to not be a risk factor for LCTs in humans (rev. in Clegg et al., 1997) . In addition, rats appear to have more than 20 000 receptors/Leydig cell, while humans have closer to 2000 LH receptors per Leydig cell (Huhtaniemi et al., 1982) , a difference which, according to the "spare receptor "hypothesis (Catt and Dufau, 1973) , should render the rat cells more susceptible to changes in circulating LH. A critical final difference is that chronic exposure to human chorionic gonadotropin, which binds to the LH receptor, is mitogenic in rats (Christensen and Peacock, 1980) but not so in humans (Heller and Leach, 1971) . Concomitantly, the spontaneous background rate of LCTs in elderly rats is 5 to >80% in SpragueDawley or Fisher rats, respectively (rev. in Clegg et al., 1997) , while the rate in humans is approximately 4 in 10 000 000 (Gilliland and Key, 1995) . These differences between the species have led to the generally accepted conclusion that LCTs in rats are irrelevant for human health risk assessment.
Effects of tofacitinib in the rat carcinogenicity study on LCT incidence in males and on mammary tissue in females were similar to those observed previously for several marketed dopamine agonists (Table 2) . Dopamine agonists reproducibly cause doserelated increases in the incidence of LCTs in male rats. In female rats dopamine agonists decrease the incidence of mammary tumors such as fibroadenomas, and decrease the incidence of findings related to prolactin-induced mammary secretory activity, eg, galactocele, cystic change. The similarities in the effects of tofacitinb to those of dopamine agonists with respect to LCTs and effects in female mammary tissue support the presumption that tofacitinib inhibited prolactin signaling in vivo at the concentrations achieved in the rat carcinogenicity study. The maximal extent of the drug-induced changes in the incidences of LCTs and mammary findings appears to be somewhat greater for the dopamine agonists compared with the maximal effects of tofacitinib. This may reflect a difference between modulating the PRL pathway via inhibition of PRL release from the pituitary versus inhibition of PRL signaling in target cells.
In summary, in the 2-year rat carcinogenicity study with tofacitinib, an increase in testicular LCTs and decreases in female mammary tumors and duct dilatation/galactocele were noted. Both of these findings can be tied together by an offtarget effect of the drug to inhibit the JAK2/STAT5 signaling through the prolactin receptor. The data showing reduced amount of phosphorylated STAT5 and amounts of LHR mRNA support this hypothesis. Finally, the differences between rats and humans with regard to PRL and Leydig cell biology and literature data from marketed dopamine agonists further support the conclusion that induction of LCTs by tofacitinib in rats is unlikely to translate to an increased risk of LCTs in humans at therapeutic tofacitinib exposures.
